13. 510(k) Summary of Safety And Effectiveness for Model LAD-08
13.1 Submitter Information
FEB 2 0 2004
Norwood Abbey Limited.
63 Wells Road
Chelsea Heights Victoria 3196
Australia
Contact Person: Paul Clark
Telephone No.: +6 1-3-9782 7308
Fax: +6 1-3-9782 7334 :
13.2 Device Name
Classification Name: — Laser surgical instrument for gencral and plastic surgery and in
dermatology
Proprietary Name: LAD, model LAD-08
13.3 Predicate Devices
LAD-01/06
13.4 Description of the Device
The Norwood Abbey Model LAD-08 is a portable, handheld, battery powered Er: YAG laser.
The radiant energy produced by this lascr has a wavelength of 2.94 um and a beam diameter or
spot-size of 6 mm at the treatment site. The radiation delivered by the device is sufficient to
remove the stratum corneum of skin exposed to the treatment.
13.5 Intended Use
The intended use of the LAD-08 is for ablation of the outer layer of the skin prior to the
application of OTC topical 4% lidocaine cream, for local dermal anesthesia.
13.6 Clinical Studies
No additional studies have been performed on the LAD-08.
Page 15

7" ;
f DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
ll ——— Ss
“ve Food and Drug Administration
9200 Corporate Boulevard
FEB 2 0 2004 Rockville MD 20850
Mr. Paul Clark
Quality and Regulatory Affairs Manager
Norwood Abbey Limited
63 Wells Road
Chelsea Heights Victoria 3196
Australia
Re: K033962
Trade/Device Name: Epiture™ Easytouch, Model LAD-08
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and
plastic surgery and in dermatology
Regulatory Class: II
Product Code: GEX
Dated: December 18, 2003
Received: December 22, 2003
Dear Mr. Clark:
We have reviewed your Section 510(k) premarket notification of intent to market the device ,
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,

‘ and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.

If your device is classified (sce above) into either class Il (Special Controls) or class If (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as sct
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Mr. Paul Clark
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The EDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled,
"Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address http://www. fda.gov/edrh/dsma/dsmamain. htm!

Sincerely yours,

Aah atl than —

S\ Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and Radiological Health
Enclosure

Norwood Abbey LAD-08 Special 510(k)
3.2 Statement of Intended Use
Page of ___
510(k) Number (if known): Ko 3 3 GOL
Device Name: _ Epiture™ Easytouch_, Model LAD-08
Indications for Use:
LAD-08 is indicated for ablation of the outer layer of the skin prior lo the application of
OTC topical 4% lidocaine cream, for local dermal anesthesia.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF
NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use kX] OR Over-The Counter Use [_]
(Per 21 CFR 801.109)
f (Division Sign-Ofi)
Division of General, Restorative,
and Neurologicai Devices
K 0383962
510(k) Number__< 557
5

